Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs Ad26 Mos4 HIV (Primary) ; HIV clade C gp140 vaccine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Imbokodo
  • Sponsors Janssen Vaccines and Prevention B.V
  • Most Recent Events

    • 18 Feb 2019 Planned End Date changed from 1 Feb 2022 to 27 May 2022.
    • 22 Oct 2018 According to a Johnson and Johnson media release, results from this trial are expected in 2021.
    • 24 Jul 2018 According to Johnson & Johnson media release, results from this trial are expected in 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top